/Dr. Bas Trietsch
Tumor organoid modeling: Bringing together the best biology to address hard-to-treat diseases
Tumor organoid modeling: Bringing together the best biology to address hard-to-treat diseases
16 May 2023

Recent advances in biological modeling mean the complex architecture of a tissue can be more accurately represented. This technology grants an improved understanding of the dynamic and complex mechanisms involved in health and disease states and provides essential insight for novel therapies development.

In this interview, Dr. Bas Trietsch, CTO and co-founder of MIMETAS, explores the company’s work generating organoids from excised tumors. Here, Trietsch explains how these tumor organoids were cultured in context – via the OrganoPlate® platform – to screen the effects of several different therapeutic options. Trietsch also shares the importance of multiplexed analysis combining high-time and spatial resolution measurements required to fully investigate the dynamic of complex tissues.

This video was filmed at SLAS2023.

Related Scientists

Related Content